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Delirium is a common and serious acute neuropsychiatric syndrome characterized by inattention and
global cognitive dysfunction. The etiologies of delirium are diverse, multifactorial, and often reﬂect the
pathophysiologic consequences of an acute medical illness, medical complication, or drug intoxication. At
present, the diagnosis of delirium depends on the presence of certain clinical features. Many recent
studies have sought to identify biomarkers for delirium to predict its onset, severity, recovery rate, or
prognosis. In this narrative review, we examine six approaches to identify serum biomarkers of delirium:
serum chemistry, genes, neurotransmitters, inﬂammatory factors, serum cortisol levels, and end prod-
ucts of delirium. Moreover, we discuss the limitations of current research and the challenges of serum
biomarker studies.
Copyright  2011, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Delirium is a common neuropsychiatric syndrome characterized
by inattention and acute cognitive dysfunction. “Delirium” has been
a medical term since the ﬁrst century, when it was used to describe
mental problems during fever or head trauma. A diverse range of
terms have been developed to describe delirium, including “acute
confusional state” and “acute brain syndrome,” among others. Over
time, the term has evolved to refer to a syndrome describing acute
and ﬂuctuating changes in consciousness that occur under medical
conditions. Delirium affects 14%e56% of elderly hospital inpatients
and is associated with signiﬁcantly longer hospital stays, the need
for institutional care, functional decline, higher mortality rates, and
greater healthcare expenditures.1 Due to its clinical importance,
extensive studies have explored the pathophysiology, treatment,
outcome, and biomarkers of delirium in the hopes of developing
predictive models for the condition.
Biomarkers are biochemical or molecular traces related to the
presence or severity of a disease. Three patterns of biomarkers
identify a disease state.2 First, a biomarker may serve as a riskKaohsiung Veterans General
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linical Gerontology & Geriatrics. Pmarker, meaning that its presence before disease onset identiﬁes
individuals at risk of the disease. Second, a biomarker may be
a diseasemarker, risingwith disease onset and falling with recovery.
Diseasemarkers are especially important because they may serve as
clues to the pathophysiology of disease. Finally, a biomarker may be
an end product of disease. Such biomarkers arise after the onset of
disease in proportion to its severity or consequence. Their presence
indicates damage caused by the disease.
Because delirium has no clear etiopathogenesis model, identi-
fying accurate biomarkers may help solve the puzzle of its patho-
physiology. Identifying biomarkers may also help diagnose delirium,
predict its time course and severity, or determine its long-term
outcome. In this narrative review, we focused on six approaches
to identify serum biomarkers for delirium: serum chemistry, genes,
neurotransmitters, inﬂammatory factors, cortisol levels, and end
products of delirium. We also discussed the advantages and limi-
tations of these approaches.
For this review we searched the literature on the electronic
databases (PubMed, Medline, Proquest Medical Library). The
primary search term usedwas “delirium”; it was also combinedwith
the following terms: biomarker, neurotransmitter, gene, cortisol,
and cytokines. All suitable publicationswere extracted for the last 15
years. Rather than conducting a systematic analysis of the literature,
we analyzed key recent articles based on our research and clinical
experience. Table 1 contains a summary of biomarkers for delirium.ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 1
Biomarkers for delirium: The summary of evidence
Biomarker Category Settings Supportive evidence
Serum chemistry Blood urine nitrogen/
creatinine ratio
Risk marker Medical and surgical wards Two small and one large scale studies with consistent reports
Electrolyte Risk marker Surgical ward Three large scale studies support
Glucose Risk marker Surgical ward One large scale study support
Albumin Risk marker Surgical ward Two small to moderate scale studies with consistent results
Gene Apolipoprotein E4 Risk marker Medical and surgical wards Three moderate scale studies with controversial results
Dopamine transporter
gene (SLC6A3)
Protective factor Medical and surgical wards One cross sectional study and Meta analysis support
Dopamine receptor 2 gene Protective factor Medical and surgical wards One cross sectional and Meta analysis showed possible relationship
Neurotransmitter Anticholinergic activity Disease marker Medical ward Several small to moderate studies with inclusive results
Serotonin Disease marker Medical ward Two review and one small scale studies support
Melatonin Disease marker Two small scale studies support
Inﬂammation C-reactive protein Disease marker
and Risk marker
Medical and surgical wards Two small to moderate scale studies with consistent conclusion
Cytokines Disease marker Medical and surgical wards Several small to moderate scale studies with no consistent
pattern of markers
Chemokines Disease marker Surgical ward One small scale study support
Chronic Stress Cortisol Disease marker Medical and surgical wards Few case reports and two small to moderate scale studies with
inconclusive reports
End products
of delirium
S100B End products Medical and surgical wards Several small to moderate scale studies support
Neuron speciﬁc enolase End products Surgical ward Two small scale studies showed no association with delirium
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Several studies have identiﬁed serum chemistries as riskmarkers
for delirium. Inouye and colleagues3 deﬁned a blood urine nitrogen
(BUN)/creatinine ratio over 18 as one of four risk markers of
delirium in hospitalized elderly. An elevated BUN/creatinine ratio
indicates dehydration, which predisposes patients to delirium.4,5
Weed and colleagues6 deﬁned abnormal serum levels of sodium,
potassium and glucose as independent risk factors for delirium.
Other biochemistry imbalances associated with increased risk of
delirium include low albumin7,8 and hypermagnesemia.5 Because
these topics have beenwell discussed in the past, few recent studies
have focused on these biomarkers.
1.2. Genetic markers
1.2.1. Apolipoprotein E4 allele
Increasing evidence points to a relationship between delirium
and dementia. Therefore, it seems reasonable that genetic risk
markers for dementia may also be risk markers for delirium. The
most researched genetic marker for dementia is the apolipoprotein
(Apo) E4 allele. However, the results are still controversial. Leung
and others9 noted that the presence of the Apo E4 allele increased
the risk of post-operative delirium after noncardiac surgery. Ada-
mis and colleagues10 proposed that the Apo E4 allele could serve as
a predictive factor for recovery from delirium. However, the study
by Tagarakis11 showed no relationship between delirium and Apo
E4 allele in patients undergoing heart bypass surgery.
1.2.2. Dopamine-related genes
Genetics of delirium due to alcohol withdrawal has been studied
more often than in elderly. Polymorphisms in the dopamine
receptor and transporter genes were found to be associated with
alcohol withdrawal delirium.12 Although the pathophysiologic
mechanisms of alcohol withdrawal delirium and delirium in the
elderly may differ, dopamine appears to have a role in both
syndromes. In the cross sectional study which participants were
recruited in medical and surgical wards, the rs393795 poly-
morphisms in the dopamine transporter gene [solute carrier family
6, member 3 (SLC6A3)] was associated to reduced risk of delirium.13
Besides, there were three polymorphisms in the dopamine receptor
2 (DRD2) gene (rs6276, rs6277, and rs2734839) were possiblyassociated with delirium.13 van Munster and others’14 meta-
analysis also showed the homozygous AA genotype of rs393795
in the SLC6A3 gene reduced risk of delirium by lower cerebral basal
dopamine concentration and a suspected protective effect of rs6276
in the DRD2 gene.
Future gene microarray analysis may help researchers locate
genetic markers by comparing microarrays between persons with
and without delirium. Data mining this information can help
determine whether certain genes are turned on or off differentially
during an episode of delirium. As in other areas, it will be important
to control for patient and insult characteristics.
1.3. Neurotransmitters
1.3.1. Acetylcholine and serum anticholinergic activity
A widely postulated mechanism for delirium is cholinergic
failure.15 The clinical observation that delirium is one manifestation
of anticholinergic toxicity16 supports this hypothesis. The anticho-
linergic burden had been identiﬁed by two different approaches.
One was evaluating the overall central anticholinergic load.17
However, mainly peripheral anticholinergic symptoms were
screened. The other approach measured the cumulative serum
anticholinergic activity (SAA) in the peripheral blood by utilizing
a radio receptor assay developed by Tune in 1980.18 In 1990s, some
authors found an association between SAA and delirium in the
elderly.19,20 However, two prospective studies have found that SAA is
not related to delirium.21,22 Themixed results might be derived from
the unproven and questionable hypothesis that peripheral serum
assay of SAA also reﬂects the central anticholinergic load.23,24 The
development of muscarinic subtype speciﬁc assays is an exciting
innovation which may help clarify the situation.25 These assays use
recombination human muscarinic speciﬁc for the ﬁve subtypes of
acetylcholine, with subtype one postulated as cognition-related.
This technique may help establish anticholinergic activity as
a biomarker for delirium.
1.3.2. Serotonin, melatonin, and other serum amino acids
Normal serotonin synthesis and release in the human brain is
dependent on the availability of its precursor tryptophan (Trp) from
blood. Trp competes with the other large neutral amino acids
(LNAA) like tyrosine and phenylalanine for transport across the
blood-brain barrier. Therefore, the plasma ratio of Trp/LNAA and
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peripheral measures of central serotonergic functioning. Both
increased and decreased serotonergic activity have been associated
with delirium.26 Elevated central nervous system serotonin activity
can be found in hepatic encephalopathy patients. Serotonin
syndrome is a main symptom of delirious patients.27 Flacker and
colleagues28 found low Trp to phenylalanine ratios and low serum
Trp levels associatedwith delirium in acutely febrile long-term care
residents.
Melatonin is a hormone that affects the propensity to sleep, its
duration, and quality. The sleep patterns of delirious patients are
usually disturbed, perhaps hinting of an association between sleep
and delirium. Shigeta and others29 observed lower postoperative
over preoperative melatonin concentrations when delirium
developed as a single complication in a small-scale study. They
concluded that abnormal melatonin secretion may be involved in
postoperative sleep disturbances, triggering delirium in elderly
patients. Later research showed a high level of melatonin in the
hypoactive type of delirium and a low level in the hyperactive type,
as measured by urinary 6-sulphatoxymelatonin, a chief metabolite
of melatonin.30 As melatonin can be administered, it warrants
further investigation as a biomarker of delirium.
Although dopamine and norepinephrine may be related in
delirium pathogenesis,31 no research within the last 15 years has
investigated them as biomarkers for delirium. Other serum amino
acids ﬂuctuate widely depending on the protein content of the
diet.27 In addition, analyzing them requires specialized processing
of the serum. These factors limit their feasibility as biomarkers for
delirium.
1.4. Inﬂammatory factors
1.4.1. C-reactive protein
Delirium is a common syndrome complex in systemic inﬂam-
matory states, including infections, cancer, and postoperative
recovery. In the brain, inﬂammatory responses modulate neuronal
functions such as neurotransmission and lead to a breakdown of
the blood-brain barrier.32 Therefore, inﬂammatory markers may
also be important biomarkers of delirium. The acute phase protein
C-reactive protein (CRP) is a traditional marker of infection,
inﬂammation and tissue injury. Evidence has recently emerged of
the relationship of CRP with neuroinﬂammatory processes. For
instance, it is associated in the activation of vascular endothelial
cells, a process that may explain the vulnerability of patients with
organic brain disease to delirium caused by systemic inﬂamma-
tion.33 It has also been correlated in a number of community
studies to poor cognitive performance and accelerated cognitive
decline.34 One study reported signiﬁcantly higher levels of CRP in
postoperative elderly with complications (infections, cardiovas-
cular problems, and delirium).35 Macdonald and colleagues36 re-
ported that CRP levels appeared to be highly predictive of both
incident delirium and recovery in 94 acutely ill patients aged 70 or
older, independent of measures of physical illness and disability.
The advantage of using CRP as a biomarker of delirium is its
widespread use inmedical practice. However, CRP actually captures
only one speciﬁc aspect of inﬂammation, perhaps not the one most
relevant to delirium.
1.5. Cytokines and chemokines
The inﬂammatory response involves a complex coordination of
cytokines, chemokines and adaptive physiologic responses
required to maintain homeostasis. Inﬂammatory cytokines are
produced by activated immune cells as part of the early ampliﬁ-
cation of the inﬂammatory response. Chemokines are locally actingcytokines that rapidly mediate leukocyte movement to sites of
inﬂammation, including across the blood-brain barrier. As early as
twenty years ago, Renault and colleagues37 noted that therapeutic
use of cytokines (mainly interferons) can induce symptoms of
delirium. Interleukin-1 can increase acetylcholinesterase activity38
and directly inhibit acetylcholine release from hippocampal
neurons.39 Three studies reported an association between
interleukin-6 (IL-6) and delirium.40,41 Two showed a relationship
between interleukin-8 and delirium.41 Adamis and colleagues10,42
found low levels of insulin-like growth factor-I (IGF-I) and higher
levels of interferondbut not IL-6 or tumor necrosis factor
alphadwas associated with onset, severity and recovery from
delirium in acutely ill older hospital patients. These patients were
hospitalized for surgery or for an acute illness. In 2008, Lemstra and
others43 reported that, in those free from acute or severe illness,
levels of CRP, IL-6, and IGF-1 did not differ between patients with
and without delirium.
In addition to inﬂammatory cytokines, one study measured the
chemokines present in post-cardiac surgery patients with delirium
using the new method of dual-channel microsphere ﬂow cytom-
etry.44 The study found elevated levels of such chemokines as
EOTAXIN and RANTES in patients who developed delirium in the
early postoperative period. The overall results are still inconclusive
and further research in larger cohorts of patients is warranted. The
challenge of such studies is to isolate the cytokines or chemokines
associated with a speciﬁc inﬂammatory response most related to
delirium and to control for confounding factors.
1.6. Chronic stress and cortisol
Chronic stress is well known to activate the sympathetic
nervous system, which, in turn, activates the hypothalamic-
pituitary axis and elevates serum cortisol. Delirium has also been
hypothesized to be associated with stress. Various studies have
found disturbances of the hypothalamic-pituitary-adrenal system
in delirious patients. Several case reports link hypo- or hyper-
cortisolemia with delirium.45 However, only a few small studies
have investigated the association between serum cortisol levels
and delirium in patients with sepsis or those undergoing hip frac-
ture surgery46,47 and the results were equivocal. Robertsson and
others48 proposed a strong relationship between delirium and
dexamethasone suppression, irrespective of age, and severity of
dementia.
1.7. End products of delirium
Patients with delirium usually recover after the underlying
cause resolves. Some patients develop sequelae of persistent
cognitive deﬁcit, which may progress to dementia.49 This condition
may reﬂect irreversible brain damage caused by the pathophysio-
logical mechanisms of delirium in the brain. Therefore, serum
biomarkers of neuronal injury or deathmay indicate delirium onset
or persistence.
1.7.1. S100B protein (S100B)
S100B belongs to the family of calcium-binding proteins, is
expressed mainly by astrocytes, and is found in both intra- and
extracellular brain tissue.50 S100B is usually elevated in blood and
in cerebrospinal ﬂuid after functional disturbance of the integrity of
the astrocytes, Schwann cells membrane or both increased
permeability of the blood-brain barrier. Elevated levels of S100B
have been shown to be associated with delirium in patients after
abdominal surgery,51,52 cardiac surgery,53 hip fracture surgery,54
and in sepsis-related delirium.46 Munster and colleagues47
compared S100B, cortisol, and IL-6 and found S100B to be the
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after adjusting for pre-existing cognitive impairment.
1.7.2. Neuron speciﬁc enolase
Neuron speciﬁc enolase (NSE) is the intracytoplasmic glycolytic
enzyme enolase. It is found in neurons and neuroendocrine tissue
and is elevated in the circulating blood when more of these cells
have died. Previous research has usually measured it with S100B.
However, it was not signiﬁcantly associated with delirium in
patients undergoing cardiac53 or abdominal51 surgery. Because of
different sources of S100B and NSE, the diverse results may reﬂect
a different underlying pathophysiology of delirium.
2. Conclusion
The research on serum biomarkers for delirium has several
common disadvantages, including small sample size, cross-
sectional design, inadequate characterization of baseline charac-
teristics of participants and, most importantly, the heterogeneous
nature of the insult leading to delirium. Each of above weakness
creates difﬁculty in isolating the impact of delirium on biomarkers
from patient-related or illness-related factors. Therefore, matching
for baseline characteristics that might be associated with
biomarker release and controlling for the insult leading to delirium
will be important steps in designing future research on delirium.
Based on these parameters, patients undergoing orthopedic
surgery may represent an appropriate study population.
Besides the methodologic limitations of current studies, two
additional challenges exist in identifying serum biomarkers for
delirium. First, a key characteristic of delirium is its ﬂuctuating
course, which makes establishing its precise onset or termination
difﬁcult. Therefore, the timing of biomarker testing for delirium can
be a challenge. Second, delirium is a central nervous system
process. Since the blood-brain barrier effectively segregates the
central nervous system from the peripheral bloodstream, obtaining
serum biomarkers indicative of central nervous system process
may be difﬁcult.
Each type of biomarkers mentioned in the review is worthy of
further investigation. In particular, those focusing on genes, the
cholinergic system and inﬂammation may be most important for
unveiling the potential linkage between dementia and delirium.
Such studies of biomarkers will increase our understanding of the
pathophysiology of delirium and ultimately improve our ability to
predict and treat delirium in patients.
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